Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase | 1.1892 | 0 | 0.5 |
Plasmodium vivax | hydroxymethylpterin pyrophosphokinase-dihydropteroate synthetase, putative | 1.1892 | 0 | 0.5 |
Mycobacterium tuberculosis | 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase FolK (7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase) ( | 3.7382 | 0.6956 | 0.5 |
Mycobacterium ulcerans | 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase | 4.8535 | 1 | 0.5 |
Toxoplasma gondii | dihydropteroate synthase | 1.1892 | 0 | 0.5 |
Chlamydia trachomatis | bifunctional 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase/dihydropteroate synthase | 1.1892 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.